Topiramate , 98% , 97240-79-4
Synonym(s):
2,3:4,5-Bis-O-(1-methylethylidene)-36-D -fructo-pyranose sulfamate;McN 4853;RWJ 17021;Topamax;Topiramate
CAS NO.：97240-79-4
Empirical Formula: C12H21NO8S
Molecular Weight: 339.36
MDL number: MFCD00865320
EINECS: 619-263-3
| Pack Size | Price | Stock | Quantity |
| 250MG | RMB19.20 | In Stock |
|
| 1G | RMB28.00 | In Stock |
|
| 5G | RMB39.20 | In Stock |
|
| 25G | RMB130.40 | In Stock |
|
| 100G | RMB444.00 | In Stock |
|
| 500g | RMB1599.20 | In Stock |
|
| others | Enquire |
PRODUCT Properties
| Melting point: | 125°C |
| alpha | D23 -34.0° (c = 0.4 in methanol) |
| Boiling point: | 438.7±55.0 °C(Predicted) |
| Density | 1.336±0.06 g/cm3(Predicted) |
| Flash point: | 9℃ |
| storage temp. | 2-8°C |
| solubility | DMSO: ~44 mg/mL |
| form | solid |
| pka | 9.22±0.70(Predicted) |
| color | white |
| Water Solubility | 9.705g/L(temperature not stated) |
| Merck | 14,9547 |
| BCS Class | 3 |
| LogP | 2.970 (est) |
| EPA Substance Registry System | .beta.-D-Fructopyranose, 2,3:4,5-bis-O-(1-methylethylidene)-, 1-sulfamate (97240-79-4) |
Description and Uses
Topiramate, a novel sulfamate-substituted D-fructose derivative, was launched in the United Kingdom as an adjunct therapy for use in partial seizures with or without secondary generalized seizures in adult patients inadequately controlled on conventional antiepileptics. Topiramate is structurally distinct from other available antiepileptics and functions through a unique combination of several mechanisms. It appears to act by blocking voltage-sensitive sodium channels to raise the action potential threshold and block the spread of seizure, enhancing GABA activity at postsynaptic GABA receptors and reducing glutamate activity at postsynaptic AMPAtype receptors, and is also a carbonic anhydrase inhibitor. Topiramate is orally active with rapid absorption, high bioavailability, and long duration of action. Excellent efficacy has been reported as an add-on therapy in epilepsy and it is also being evaluated as a monotherapy.
Used for the treatment and control of partial seizures and severe tonic-clonic (grand mal) seizures and also for the prevention of migraine headaches. In children it is also used for treatment of Lennox-Gastaut syndrome. Qsymia? is indicated for the treat
Safety
| Symbol(GHS) |  GHS07 |
| Signal word | Warning |
| Hazard statements | H315-H319-H335 |
| Precautionary statements | P261-P264-P271-P280-P302+P352-P305+P351+P338 |
| Hazard Codes | Xi,T,F |
| Risk Statements | 36/37/38-39/23/24/25-23/24/25-11 |
| Safety Statements | 26-36-45-36/37-16-7 |
| RIDADR | UN1230 - class 3 - PG 2 - Methanol, solution |
| WGK Germany | 3 |
| RTECS | LS7083000 |
| HS Code | 29350090 |
| Hazardous Substances Data | 97240-79-4(Hazardous Substances Data) |
| Toxicity | LD50 intraperitoneal in rat: > 1500mg/kg |
